Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid

Jean Pierre Devogelaer, Piet Geusens, Evis Daci, Evelien Gielen, Kris Denhaerynck, Karen MacDonald, Christine Hermans, Stefaan Vancayzeele, Ivo L Abraham, Steven Boonen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Using data from the Belgian Paget's Disease Registry of 142 patients treated with a 5 mg intravenous infusion of zoledronic acid, we examined disease remission over 3 years in 98 patients with Paget disease of bone (PDB) seen in routine practice. Median age was 76 years, most patients (60.2 %) were male, and all were Caucasian. Median time since PDB diagnosis was 11.5 years, few patients (5.1 %) had a family history of PDB, and 32.6 % had received prior bisphosphonate and/or other treatments. The most common pagetic locations were pelvis, spine, femur, tibia, and skull. The most common symptoms included pain, impaired mobility, bone deformities, and joint disease: 36.7 % of patients had comorbid osteoarthritis and 16.3 % comorbid osteoporosis. Response rates were 93.3 % at 1 year, 89.5 % at 2 years, and 91.6 % at 3 years, statistically similar to an extension study of the original zoledronic acid trials. Twenty-one patients experienced a relapse over the 3-year period at a median of 20.7 months posttreatment; of these, 13 regained remission by the end of the observation period. Relapse was not associated with osteoarthritis, osteoporosis, or other comorbidities. Safety data were similar to those reported elsewhere. In summary, in this somewhat frailer sample of patients with PDB, effectiveness and safety data were similar to those observed in the original trial populations. These findings, which are the first on the use of zoledronic acid for PDB in routine clinical practice, underscore the therapeutic benefits and relative safety of zoledronic acid in the management of PDB in "real-world" clinical settings.

Original languageEnglish (US)
Pages (from-to)311-318
Number of pages8
JournalCalcified Tissue International
Volume94
Issue number3
DOIs
StatePublished - 2014

Fingerprint

zoledronic acid
Osteitis Deformans
Intravenous Infusions
Safety
Osteoarthritis
Osteoporosis
Recurrence
Joint Diseases
Bone Diseases
Diphosphonates
Pelvis
Tibia
Skull
Femur
Registries
Comorbidity

Keywords

  • Bisphosphonate
  • Paget disease of bone
  • Remission
  • Treatment
  • Zoledronic acid

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid. / Devogelaer, Jean Pierre; Geusens, Piet; Daci, Evis; Gielen, Evelien; Denhaerynck, Kris; MacDonald, Karen; Hermans, Christine; Vancayzeele, Stefaan; Abraham, Ivo L; Boonen, Steven.

In: Calcified Tissue International, Vol. 94, No. 3, 2014, p. 311-318.

Research output: Contribution to journalArticle

Devogelaer, JP, Geusens, P, Daci, E, Gielen, E, Denhaerynck, K, MacDonald, K, Hermans, C, Vancayzeele, S, Abraham, IL & Boonen, S 2014, 'Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid', Calcified Tissue International, vol. 94, no. 3, pp. 311-318. https://doi.org/10.1007/s00223-013-9812-9
Devogelaer, Jean Pierre ; Geusens, Piet ; Daci, Evis ; Gielen, Evelien ; Denhaerynck, Kris ; MacDonald, Karen ; Hermans, Christine ; Vancayzeele, Stefaan ; Abraham, Ivo L ; Boonen, Steven. / Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid. In: Calcified Tissue International. 2014 ; Vol. 94, No. 3. pp. 311-318.
@article{efadc0180fe54c75ae6d8a9e5577b085,
title = "Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid",
abstract = "Using data from the Belgian Paget's Disease Registry of 142 patients treated with a 5 mg intravenous infusion of zoledronic acid, we examined disease remission over 3 years in 98 patients with Paget disease of bone (PDB) seen in routine practice. Median age was 76 years, most patients (60.2 {\%}) were male, and all were Caucasian. Median time since PDB diagnosis was 11.5 years, few patients (5.1 {\%}) had a family history of PDB, and 32.6 {\%} had received prior bisphosphonate and/or other treatments. The most common pagetic locations were pelvis, spine, femur, tibia, and skull. The most common symptoms included pain, impaired mobility, bone deformities, and joint disease: 36.7 {\%} of patients had comorbid osteoarthritis and 16.3 {\%} comorbid osteoporosis. Response rates were 93.3 {\%} at 1 year, 89.5 {\%} at 2 years, and 91.6 {\%} at 3 years, statistically similar to an extension study of the original zoledronic acid trials. Twenty-one patients experienced a relapse over the 3-year period at a median of 20.7 months posttreatment; of these, 13 regained remission by the end of the observation period. Relapse was not associated with osteoarthritis, osteoporosis, or other comorbidities. Safety data were similar to those reported elsewhere. In summary, in this somewhat frailer sample of patients with PDB, effectiveness and safety data were similar to those observed in the original trial populations. These findings, which are the first on the use of zoledronic acid for PDB in routine clinical practice, underscore the therapeutic benefits and relative safety of zoledronic acid in the management of PDB in {"}real-world{"} clinical settings.",
keywords = "Bisphosphonate, Paget disease of bone, Remission, Treatment, Zoledronic acid",
author = "Devogelaer, {Jean Pierre} and Piet Geusens and Evis Daci and Evelien Gielen and Kris Denhaerynck and Karen MacDonald and Christine Hermans and Stefaan Vancayzeele and Abraham, {Ivo L} and Steven Boonen",
year = "2014",
doi = "10.1007/s00223-013-9812-9",
language = "English (US)",
volume = "94",
pages = "311--318",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid

AU - Devogelaer, Jean Pierre

AU - Geusens, Piet

AU - Daci, Evis

AU - Gielen, Evelien

AU - Denhaerynck, Kris

AU - MacDonald, Karen

AU - Hermans, Christine

AU - Vancayzeele, Stefaan

AU - Abraham, Ivo L

AU - Boonen, Steven

PY - 2014

Y1 - 2014

N2 - Using data from the Belgian Paget's Disease Registry of 142 patients treated with a 5 mg intravenous infusion of zoledronic acid, we examined disease remission over 3 years in 98 patients with Paget disease of bone (PDB) seen in routine practice. Median age was 76 years, most patients (60.2 %) were male, and all were Caucasian. Median time since PDB diagnosis was 11.5 years, few patients (5.1 %) had a family history of PDB, and 32.6 % had received prior bisphosphonate and/or other treatments. The most common pagetic locations were pelvis, spine, femur, tibia, and skull. The most common symptoms included pain, impaired mobility, bone deformities, and joint disease: 36.7 % of patients had comorbid osteoarthritis and 16.3 % comorbid osteoporosis. Response rates were 93.3 % at 1 year, 89.5 % at 2 years, and 91.6 % at 3 years, statistically similar to an extension study of the original zoledronic acid trials. Twenty-one patients experienced a relapse over the 3-year period at a median of 20.7 months posttreatment; of these, 13 regained remission by the end of the observation period. Relapse was not associated with osteoarthritis, osteoporosis, or other comorbidities. Safety data were similar to those reported elsewhere. In summary, in this somewhat frailer sample of patients with PDB, effectiveness and safety data were similar to those observed in the original trial populations. These findings, which are the first on the use of zoledronic acid for PDB in routine clinical practice, underscore the therapeutic benefits and relative safety of zoledronic acid in the management of PDB in "real-world" clinical settings.

AB - Using data from the Belgian Paget's Disease Registry of 142 patients treated with a 5 mg intravenous infusion of zoledronic acid, we examined disease remission over 3 years in 98 patients with Paget disease of bone (PDB) seen in routine practice. Median age was 76 years, most patients (60.2 %) were male, and all were Caucasian. Median time since PDB diagnosis was 11.5 years, few patients (5.1 %) had a family history of PDB, and 32.6 % had received prior bisphosphonate and/or other treatments. The most common pagetic locations were pelvis, spine, femur, tibia, and skull. The most common symptoms included pain, impaired mobility, bone deformities, and joint disease: 36.7 % of patients had comorbid osteoarthritis and 16.3 % comorbid osteoporosis. Response rates were 93.3 % at 1 year, 89.5 % at 2 years, and 91.6 % at 3 years, statistically similar to an extension study of the original zoledronic acid trials. Twenty-one patients experienced a relapse over the 3-year period at a median of 20.7 months posttreatment; of these, 13 regained remission by the end of the observation period. Relapse was not associated with osteoarthritis, osteoporosis, or other comorbidities. Safety data were similar to those reported elsewhere. In summary, in this somewhat frailer sample of patients with PDB, effectiveness and safety data were similar to those observed in the original trial populations. These findings, which are the first on the use of zoledronic acid for PDB in routine clinical practice, underscore the therapeutic benefits and relative safety of zoledronic acid in the management of PDB in "real-world" clinical settings.

KW - Bisphosphonate

KW - Paget disease of bone

KW - Remission

KW - Treatment

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84895418692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895418692&partnerID=8YFLogxK

U2 - 10.1007/s00223-013-9812-9

DO - 10.1007/s00223-013-9812-9

M3 - Article

C2 - 24271562

AN - SCOPUS:84895418692

VL - 94

SP - 311

EP - 318

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 3

ER -